Mats Magnusson, Ph.D.

Principal Consultant, Acting QC/MW Manager & Deputy COO

Bio

  • Co-founded Pharmetheus in 2012, actively working in client projects, as Project Portfolio Team Leader managing teams of MIDD, QC & Medical Writing and Data Programming Consultants, and serving as Deputy Chief Operations Officer.
  • Expertise includes reproducible reporting, pediatrics, and trial design across therapeutic areas.
  • Experience as Consultant and Senior Consultant at Exprimo NV, Sweden, where he interacted with clients and provided pharmacokinetic, pharmacodynamic, disease modeling and simulation services to drug development programs in various therapeutic areas. Previously, he worked as Pharmacometrician at Pfizer PGRD, UK.
  • M.Sc. in Pharmacy (2001) and Ph.D. in Biopharmaceutical Sciences (2007) from Uppsala University, Sweden.
LinkedInGoogle Scholar

Pharmetheus affiliated publications

A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology frameworkWriting reports of modelling and simulation analysis: Our experience in the field of pharmacometricsPopulation Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus ErythematosusPopulation Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic StrokeExposure-Efficacy Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung DiseaseComparison of Quality of Urinary Bladder Filling in CT Urography with Different Doses of Furosemide in the Work-Up of Patients with Macroscopic HematuriaPopulation Pharmacokinetic and Exposure-Response Models for Dapirolizumab Pegol in Patients with Systemic Lupus ErythematosusPopulation PK and PASI Exposure-Response Modelling for Certolizumab Pegol in Patients with Chronic Plaque PsoriasisPharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting WorkflowBridging Physiologically Based Pharmacokinetic (PBPK) and Population Pharmacokinetic (PopPK) Analyses in Paediatric Drug Development: A Case Study Based on Intravenous EsomeprazoleDosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data